Study of the inhibitory effect of Silver Nanoparticles on Extensively Drug-resistant Mycobacterium Tuberculosis (TB) strains
DOI:
https://doi.org/10.52340/spectri.2024.09.01.12Keywords:
Silver Nanoparticles, pre-extensively drug-resistant Tuberculosis, Mycobacterium TuberculosisAbstract
Introduction: One of crucial focus within phthisiology is the exploration and analyses of substances capable of overcoming resistance to anti-TB medications in drug-resistant mycobacterium TB strains. While substantial experimental data confirm the bactericidal effect of silver nanoparticles (AgNPs) on various drug-resistant strains, there remains the notable gap in understanding their action against Mycobacterium tuberculosis(MTB), particularly in drug-resistant cases. The inhibitory efficacy of AgNPs on MTB strains causing pre-XDR-TB has remained largely unexplored. Our study was specifically aimed at investigating this aspect. Methods: In this study, 20-nanometer AgNPs were used. To create the nanoparticle suspension, a high-frequency ultrasound homogenizer disruptor disintegrator (Ultrasonic Processor FS-1800N) was utilized. The in vitro experiment was conducted using 35 cultures of rifampicin and fluoroquinolone-resistant Mycobacterium TB (pre-XDR-MTB) obtained from participants’ sputum samples with tuberculosis. The experiment was conducted in a liquid media using BACTEC MGIT 960 system. Results: The conducted study demonstrated that adding 0.25%, 0.5% and 1.0% AgNPs suspensions to pre-XDR-MTB strains was completely ineffective; The growth of preXDR-MTB strains was inhibited, with minimal inhibitory effects observed when using a 2.5% AgNPs solution. Complete inhibition and a bactericidal effect were noted with the addition of 5% and 10% AgNPs solutions. Conclusion: The experimental study confirmed the inhibitory effect of AgNPs on preXDR-MTB strains. These results provide a solid foundation for further research to investigate the safety of using AgNPs and their potential to restore the efficacy of anti-TB medications.
Downloads
References
WHO. Global antimicrobial resistance and use surveillance system (GLASS) report: 2022: 1-4.
Patel J, Harant A, Fernandes G, Mwamelo AJ, Hein W, Dekker D. Measuring the global response to antimicrobial resistance, 2002-21: a systematic governance analysis of 114 countries. The Lancet, Infectious diseases. 2023; 23 (6):706-718.
WHO. Consolidated guidelines on tuberculosis: module 4: treatment: drug-resistant tuberculosis treatment. 2022.
WHO. Global tuberculosis report. 2023.
Uba Bo, Okoye EL, Anyichie JC, Dokubo CU, Uqwuojj ET. Measuring the global response to antimicrobial resistance.Journal of Advances in microbiology.2024; (3):65-78.
Sadhu S, Karmakar T, Chatterjee AG, Kumari U, Mondal P, Sarka S, Sur T, Tarafdar S. International Journal of Experimental Research and Review. 2022 (29):67-72.
F. Andrade F. Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases. Advanced Drug Delivery Reviews.2013 (l65): 1816-1827.
Parashar s, Sharma MK, Garg Ch, Garg M. Green Synthesized Silver Nanoparticles as Silver Lining in Antimicrobial Resistance: A Review. Current Drug Delivary. 2022 (19):170-181.
Farooq U, Ahmad T, Khan A,Sarwar R, Shafig J, Raza Y, Ahmed A, Ullah S, Rehman NU, Al-Harrasi A. Rifampicin conjugated silver nanoparticles: a new arena for development of antibiofilm potential against methicillin resistant Staphylociccus aureus and Klebsiella pneumoniae. International Journal Nanomedicine. 2019 (14):3983-3993.
Zaharov AV, Khokhlov AL, Ergeshov AE. Silver nanoparticles in the solution of the problem of drug resistance in mycobacterium tuberculosis. Archive of Internal Medicine. 2017 (3):188-199.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.